aTyr Pharma ATYR 深 沪
等待开盘 09-23 09:30:00 美东时间
0.3564
-0.016
-4.40%
华盛通- 最 高0.3816
- 今 开0.3816
- 成交量 133.58万股
- 最 低 0.351
- 昨 收 0.3728
- 总市值 3495.84万
- 52周最高 1.12
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 0.351
- 委 比 -33.33%
- 总股本 9808.74万
- 历史最高 396.06
- 量 比 1.28
- 振 幅 8.21%
- 历史最低 0.351
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing of a response from the U.S. Food and D...
09-02 04:37
aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 50 percent increase over losses of $(0.22) per share from the same period last year.
08-08 04:02
aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod
aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod
08-01 04:50
aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmo...
07-15 20:07
aTyr Pharma Granted Nasdaq Extension to Regain Compliance
aTyr Pharma ( ($ATYR) ) has provided an announcement. On December 4, 2025, aTyr...
06-09 05:12
aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the
05-15 20:17
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12....
05-13 01:06
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma announced plans to advance efzofitimod for pulmonary sarcoidosis following FDA feedback. The company will initiate a new Phase 3 study targeting patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease, using forced vital capacity (FVC) as the primary endpoint and the King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint. The IND submission for this trial is planned for June 2026. T...
05-11 20:01
aTyr Pharma GAAP EPS of -$0.14 beats by $0.02
aTyr Pharma press release (ATYR): Q4 GAAP EPS of -$0.14 beats by $0.02. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. More on aTyr Pharma aTyr Pharma to mee...
03-06 14:24
aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 13.04 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the
03-06 05:03
